Markus Dold

Also affiliated with Comprehensive Cancer Center Vienna, Medical University of Vienna

MedicineNeurosciencePsychology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study”.

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study

European Neuropsychopharmacology(2025)10.1016/j.euroneuro.2024.12.013

N/A

0.406DataRank · unranked

14 citations

Nahida Ahmed, Celso Arango, Anthony J. Cleare, Koen Demyttenaere, Markus Dold +9 more